Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B1 and human liver S9 in mammalian cells

D. E. Goeger, A. W. Hsie, Karl Anderson

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Coumarin (1,2-benzopyrone), a natural dietary constituent and drug currently under evaluation for treatment of certain cancers and lymphedema, reduces polycyclic aromatic hydrocarbon-induced neoplasms in rodents. Because most rodents metabolize coumarin through 3,4-epoxidation, whereas 7-hydroxylation predominates in humans, their suitability as a model for coumarin effects in humans has been questioned. We examined coumarin chemoprotection against the promutagen and dietary contaminant aflatoxin B1 with human liver S9 bioactivation in the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyltransferase mutation assay. Coumarin in the absence of aflatoxin B1 was not mutagenic or cytotoxic up to 500 μM. When included with either 1 or 10 μM aflatoxin B1, coumarin produced a dose-dependent increase in mutant frequency and cytotoxicity. At concentrations greater than 50 μM, coumarin stimulated human liver S9 bioactivation of aflatoxin B1 to the mutagenic 8,9-epoxide. This increase was 12- and fivefold at 500 μM coumarin with 1 and 10 μM aflatoxin B1, respectively, compared with incubations with aflatoxin B1 alone. These findings differ from previous results with liver S9 from other species, and indicate that coumarin co-mutagenicity with aflatoxin B1 and human liver S9 is through increased aflatoxin B1 bioactivation. Copyright (C) 1999 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)581-589
Number of pages9
JournalFood and Chemical Toxicology
Volume37
Issue number6
DOIs
StatePublished - Jun 1999

Fingerprint

Aflatoxin B1
mutagenicity
coumarin
aflatoxin B1
Liver
Cells
liver
cells
Rodentia
rodents
Hypoxanthine Phosphoribosyltransferase
hypoxanthine
neoplasms
Lymphedema
guanine
Polycyclic Aromatic Hydrocarbons
Hydroxylation
Chinese hamsters
hydroxylation
Epoxidation

Keywords

  • Aftatoxin B
  • CHO/HPRT mutation assay
  • Coumarin
  • Liver S9

ASJC Scopus subject areas

  • Food Science
  • Toxicology

Cite this

Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B1 and human liver S9 in mammalian cells. / Goeger, D. E.; Hsie, A. W.; Anderson, Karl.

In: Food and Chemical Toxicology, Vol. 37, No. 6, 06.1999, p. 581-589.

Research output: Contribution to journalArticle

@article{2599a4a252e14046949e7f0452eb3a90,
title = "Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B1 and human liver S9 in mammalian cells",
abstract = "Coumarin (1,2-benzopyrone), a natural dietary constituent and drug currently under evaluation for treatment of certain cancers and lymphedema, reduces polycyclic aromatic hydrocarbon-induced neoplasms in rodents. Because most rodents metabolize coumarin through 3,4-epoxidation, whereas 7-hydroxylation predominates in humans, their suitability as a model for coumarin effects in humans has been questioned. We examined coumarin chemoprotection against the promutagen and dietary contaminant aflatoxin B1 with human liver S9 bioactivation in the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyltransferase mutation assay. Coumarin in the absence of aflatoxin B1 was not mutagenic or cytotoxic up to 500 μM. When included with either 1 or 10 μM aflatoxin B1, coumarin produced a dose-dependent increase in mutant frequency and cytotoxicity. At concentrations greater than 50 μM, coumarin stimulated human liver S9 bioactivation of aflatoxin B1 to the mutagenic 8,9-epoxide. This increase was 12- and fivefold at 500 μM coumarin with 1 and 10 μM aflatoxin B1, respectively, compared with incubations with aflatoxin B1 alone. These findings differ from previous results with liver S9 from other species, and indicate that coumarin co-mutagenicity with aflatoxin B1 and human liver S9 is through increased aflatoxin B1 bioactivation. Copyright (C) 1999 Elsevier Science Ltd.",
keywords = "Aftatoxin B, CHO/HPRT mutation assay, Coumarin, Liver S9",
author = "Goeger, {D. E.} and Hsie, {A. W.} and Karl Anderson",
year = "1999",
month = "6",
doi = "10.1016/S0278-6915(99)00046-0",
language = "English (US)",
volume = "37",
pages = "581--589",
journal = "Food and Chemical Toxicology",
issn = "0278-6915",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Co-mutagenicity of coumarin (1,2-benzopyrone) with aflatoxin B1 and human liver S9 in mammalian cells

AU - Goeger, D. E.

AU - Hsie, A. W.

AU - Anderson, Karl

PY - 1999/6

Y1 - 1999/6

N2 - Coumarin (1,2-benzopyrone), a natural dietary constituent and drug currently under evaluation for treatment of certain cancers and lymphedema, reduces polycyclic aromatic hydrocarbon-induced neoplasms in rodents. Because most rodents metabolize coumarin through 3,4-epoxidation, whereas 7-hydroxylation predominates in humans, their suitability as a model for coumarin effects in humans has been questioned. We examined coumarin chemoprotection against the promutagen and dietary contaminant aflatoxin B1 with human liver S9 bioactivation in the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyltransferase mutation assay. Coumarin in the absence of aflatoxin B1 was not mutagenic or cytotoxic up to 500 μM. When included with either 1 or 10 μM aflatoxin B1, coumarin produced a dose-dependent increase in mutant frequency and cytotoxicity. At concentrations greater than 50 μM, coumarin stimulated human liver S9 bioactivation of aflatoxin B1 to the mutagenic 8,9-epoxide. This increase was 12- and fivefold at 500 μM coumarin with 1 and 10 μM aflatoxin B1, respectively, compared with incubations with aflatoxin B1 alone. These findings differ from previous results with liver S9 from other species, and indicate that coumarin co-mutagenicity with aflatoxin B1 and human liver S9 is through increased aflatoxin B1 bioactivation. Copyright (C) 1999 Elsevier Science Ltd.

AB - Coumarin (1,2-benzopyrone), a natural dietary constituent and drug currently under evaluation for treatment of certain cancers and lymphedema, reduces polycyclic aromatic hydrocarbon-induced neoplasms in rodents. Because most rodents metabolize coumarin through 3,4-epoxidation, whereas 7-hydroxylation predominates in humans, their suitability as a model for coumarin effects in humans has been questioned. We examined coumarin chemoprotection against the promutagen and dietary contaminant aflatoxin B1 with human liver S9 bioactivation in the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyltransferase mutation assay. Coumarin in the absence of aflatoxin B1 was not mutagenic or cytotoxic up to 500 μM. When included with either 1 or 10 μM aflatoxin B1, coumarin produced a dose-dependent increase in mutant frequency and cytotoxicity. At concentrations greater than 50 μM, coumarin stimulated human liver S9 bioactivation of aflatoxin B1 to the mutagenic 8,9-epoxide. This increase was 12- and fivefold at 500 μM coumarin with 1 and 10 μM aflatoxin B1, respectively, compared with incubations with aflatoxin B1 alone. These findings differ from previous results with liver S9 from other species, and indicate that coumarin co-mutagenicity with aflatoxin B1 and human liver S9 is through increased aflatoxin B1 bioactivation. Copyright (C) 1999 Elsevier Science Ltd.

KW - Aftatoxin B

KW - CHO/HPRT mutation assay

KW - Coumarin

KW - Liver S9

UR - http://www.scopus.com/inward/record.url?scp=0032861823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032861823&partnerID=8YFLogxK

U2 - 10.1016/S0278-6915(99)00046-0

DO - 10.1016/S0278-6915(99)00046-0

M3 - Article

C2 - 10478826

AN - SCOPUS:0032861823

VL - 37

SP - 581

EP - 589

JO - Food and Chemical Toxicology

JF - Food and Chemical Toxicology

SN - 0278-6915

IS - 6

ER -